Dr Reddys Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Dr Reddys Laboratories has allotted 10,275 equity shares under ESOPs on 12 March 2026.

Powered by Capital Market - Live News

The USFDA classified the inspection outcome as ?Voluntary Action Indicated? (VAI) and confirmed that the inspection has been officially closed under 21 CFR 20.64(d)(3).

The inspection included both a Good Manufacturing Practice (GMP) review and a Pre-Approval Inspection (PAI) conducted at the company?s FTO-SEZ PU01 facility. The company had earlier informed about the USFDA inspection on 12 December 2025.

Hyderabad-based Dr Reddy?s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

Dr Reddy?s Laboratories reported a 14.4% decline in consolidated net profit to Rs 1,209.8 crore despite a 4.4% jump in revenue to Rs 8,716.8 crore in Q3 FY26 over Q3 FY25.

The counter shed 0.91% to Rs 1,301.10 on the BSE.

Powered by Capital Market - Live News

Based in UK, the Mercury Pharma Group is a specialty pharmaceutical company.

Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis.

Cyclo Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components.

As per IQVIA MAT December 2025, the Progynova brand had recorded sales of Rs 100 crore.

The company stated that this acquisition would strengthen Dr. Reddy?s gynaecology portfolio and mark its strategic entry into the hormone replacement therapy segment.

The total cost of this acquisition of $32.15 million, which at the prevailing exchange rate of Rs 91.09 per dollar, translates to Rs 292.85 crore.

M.V. Ramana, chief executive officer, branded markets (India and Emerging Markets), Dr. Reddy?s, said: The acquisition will serve as the spearhead of our expansion into the HRT segment, strengthening our existing gynaecology portfolio in India.

With our established market access, we are uniquely positioned to extend the reach of the acquired assets and deliver greater impact.

Hyderabad-based Dr. Reddy?s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company had reported a 14.4% decline in consolidated net profit to Rs 1,209.8 crore despite of 4.4% jump in revenue to Rs 8,716.8 crore in Q3 FY26 over Q3 FY25.

The scrip rose 0.21% to currently trade at Rs 1283.55 on the BSE.

Powered by Capital Market - Live News

The revenue growth was broad-based across key markets, except for North America Generics which reported a decline primarily on account of lower Lenalidomide sales. Growth was further aided by favourable foreign exchange rate movements.

Profit before tax (PBT) dropped 17.68% YoY to Rs 1,542.9 crore during the quarter.

EBITDA stood at Rs 2,049.3 crore, registering de-growth of 12.84% compared with Rs 2351.1 crore posted in corresponding quarter last year. EBITDA margin reduced to 23.5% in Q3 FY26 as against 26.7% in Q3 FY25.

Revenue from global generics increased 7% YoY to Rs 7,911.3 crore during the quarter.

In Q3 FY26, revenue from North America declined 20% YoY to Rs 2,964.4 crore, primarily due to lower Lenalidomide sales and higher price erosion in certain key products. The North America region accounted for 34% of total revenue during the quarter.

Revenue from Europe region increased 20% YoY to Rs 1447.6 crore during the quarter, supported by new generic product launches, growth witnessed in the nicotine replacement therapy (NRT) portfolio and favourable forex movements. These positives were partly offset by pricing pressure in generics.

Revenue from India jumped 19% YoY to Rs 1,603.2 crore in Q3 FY26, driven by strong performance of the innovation portfolio, new brand launches, price increases, higher volumes, and contributions from the recently acquired Stugeron portfolio. India contributed 18% of total revenue during the quarter.

Revenue from emerging markets surged 32% YoY to Rs 1896.1 crore, largely driven by new product launches across markets, aided by favourable forex.

R&D Expenses stood at Rs 614.9 crore during the quarter, registering a 8% YoY decline due to reduced development spending in biosimilars following completion of a large part of the investments related to Abatacept. R&D spends remain focused on complex generics, biosimilars, peptides and novel biologics. The quarter?s R&D spend also included a one-time provision related to new labour codes. Excluding this one-off item, R&D expenditure stood at 6.8% of revenues for the quarter.

Co-chairman & MD, G V Prasad said: Our growth in Q3FY26 was supported by continued momentum in our branded businesses, aided by favourable forex, thus offsetting the impact of lower Lenalidomide sales. We continue to focus on disciplined execution of our strategic priorities of base business growth, pipeline advancement, operational efficiencies, and select inorganic opportunities, to create long-term value for our stakeholders.

Hyderabad-based Dr. Reddy?s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The scrip rallied 4.48% to Rs 1207.30 on the BSE.

Powered by Capital Market - Live News